BeiGene (06160) announced interim results with net profit of US$464 million, up 385.8% year on year

According to the Zhitong Finance App, BeiGene (06160) announced interim results for the six months ended June 30, 2026, with revenue of US$3.119 billion, up 32.3% year on year; net profit of US$464 million, up 385.8% year on year; basic income per share of $0.32.

According to the announcement, the total global revenue for the second quarter of 2026 increased by 30% to reach US$1.7 billion; global revenue for the second quarter of 2025 increased 31% from the second quarter of 2025 to reach US$1.2 billion; the diluted income (GAAP) per share of American Depositary Receipts (ADS) was US$2.05, and the non-GAAP diluted earnings per ADS share was US$3.84.

In the six months ending June 30, 2026, total revenue increased by 32.3%. This was mainly due to an increase in sales of the company's self-developed products Baiyuze® and Baizean®, as well as an increase in sales of Amgen authorized products. Net product revenue increased 31.4% year over year, mainly due to increased sales of Baiyue® worldwide, and its growth was mainly driven by continued growth in the US and European markets. Furthermore, in the six months ending June 30, 2026, sales of Baizean® and Amgen authorized products, mainly Agave®, had a positive impact on product revenue.

The business model is sustainable and has achieved a strong global financial position. We believe the company is in a good financial position. As of June 30, 2026, our cash and cash equivalents reached US$5.1 billion. In the first half of 2026, product revenue, including the current product portfolio and core products, increased 31.4% year over year, and we expect product revenue to increase significantly in the second half of 2026 and beyond. In the first half of 2026, our GAAP net profit and non-GAAP net profit increased further, reaching US$464 million and US$820 million respectively; net cash from operating activities continued to be positive and free cash flow reached US$596 million. We will continue to deploy funds carefully and strategically, continue our previous model of cooperation, and actively seek partnerships that can strengthen our business. We are committed to creating long-term value for our shareholders.